HER2表达、检测偏差及其对转移性胃癌生存的影响:VARIANZ前瞻性多中心研究
中央与本地检测结果偏差率高达22.7%。接受曲妥珠单抗治疗且中央确认HER2阳性者中位生存20.5个月,而本地阳性但中央阴性者仅10.9个月(HR 0.42,P<.001)。
要点
- 中央与本地HER2检测偏差率22.7%,主要见于HER2中等表达标本。
- 中央确认HER2阳性者接受曲妥珠单抗生存显著优于未确认者(20.5 vs 10.9个月)。
- 预测曲妥珠单抗获益的优化阈值为HER2阳性肿瘤细胞≥40%且HER2扩增比≥3.0。
核心结论
- 转移性胃癌HER2检测在中等表达标本中存在显著偏差,临界阳性和表达异质性应视为HER2靶向治疗的耐药因素。
- 应考虑重新审视HER2阈值,详细报告HER2表达和扩增水平量化可能改善患者选择。
研究设计与样本
- 前瞻性多中心研究,在35个德国中心招募接受药物治疗的转移性胃癌患者,随访长达48个月。
主要发现
- 中央评估确认77例(14.1%)为HER2阳性转移性胃癌。
- 中央与本地检测结果偏差率为22.7%。
- 接受曲妥珠单抗治疗且中央确认HER2阳性(中央阳性/本地阳性)患者中位生存20.5个月(n=60),本地阳性但中央阴性者中位生存10.9个月(n=65),HR 0.42(95%CI 8.2-14.4),P<.001。
- 中央确认队列中HER2阳性肿瘤细胞比例显著更高,HER2扩增比显著更高。
- 预测曲妥珠单抗获益的优化阈值为HER2阳性肿瘤细胞≥40%且HER2扩增比≥3.0。
关键数值与推荐
- HER2阳性肿瘤细胞最低40%且HER2扩增比≥3.0为计算出的预测曲妥珠单抗获益的优化阈值。
临床怎么用
- 转移性胃癌HER2检测应关注中央与本地结果的一致性,对临界阳性或异质性表达病例需谨慎解读。
- 曲妥珠单抗治疗选择应参考HER2阳性肿瘤细胞比例和扩增比量化水平,而非仅定性阳性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Trastuzumab is the only approved targeted drug for first-line treatment of human epidermal growth factor receptor 2-positive (HER2+) metastatic gastric cancer (mGC). However, not all patients respond and most eventually progress. The multicenter VARIANZ study aimed to investigate the background of response and resistance to trastuzumab in mGC. METHODS: Patients receiving medical treatment for mGC were prospectively recruited in 35 German sites and followed for up to 48 months. HER2 status was assessed centrally by immunohistochemistry and chromogenic in situ hybridization. In addition, HER2 gene expression was assessed using qPCR. RESULTS: Five hundred forty-eight patients were enrolled, and 77 had HER2+ mGC by central assessment (14.1%). A high deviation rate of 22.7% between central and local test results was seen. Patients who received trastuzumab for centrally confirmed HER2+ mGC (central HER2+/local HER2+) lived significantly longer as compared with patients who received trastuzumab for local HER2+ but central HER2- mGC (20.5 months, n = 60 v 10.9 months, n = 65; hazard ratio, 0.42; 95% CI, 8.2 to 14.4; P < .001). In the centrally confirmed cohort, significantly more tumor cells stained HER2+ than in the unconfirmed cohort, and the HER2 amplification ratio was significantly higher. A minimum of 40% HER2+ tumor cells and a HER2 amplification ratio of ≥ 3.0 were calculated as optimized thresholds for predicting benefit from trastuzumab. CONCLUSION: Significant discrepancies in HER2 assessment of mGC were found in tumor specimens with intermediate HER2 expression. Borderline HER2 positivity and heterogeneity of HER2 expression should be considered as resistance factors for HER2-targeting treatment of mGC. HER2 thresholds should be reconsidered. Detailed reports with quantification of HER2 expression and amplification levels may improve selection of patients for HER2-directed treatment.
引用
- Haffner I, Schierle K, Raimúndez E, et al. HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study. J Clin Oncol. 2021. PMID: 33764808. doi:10.1200/JCO.20.02761
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。